Managed Healthcare Executive July 15, 2024
The switch to biosimilars helped Navitus clients offset increased utilization in the non-specialty category and the introduction of higher-cost specialty drugs.
Overall, Navitus’ commercial clients saw a 6.8% increase in their prescription drug trend in 2023, according to the company’s Drug Trend Report. Several industry trends have led to increased spending on prescription drugs, including rising drug costs, higher utilization in the non-specialty category, clinical advancements and the introduction of higher-cost specialty drugs.
“The biggest thing that stands out is non-specialty growth,” Ryan Schmidt, associate director, client financial support of Navitus, said in an interview. “We’ve been doing this for quite a few years, and this is the first time in a while that non-specialty drugs have exceeded specialty growth.”
...Today's Sponsors
Today's Sponsor